Giulio Pierleoni
Giulio obtained a Bachelor’s Degree in Biotechnology at the University of Urbino in 2019. In the same year, he started an internship in the Biochemistry and Molecular Biology Lab “G. Fornaini” at the University of Urbino focused on the protein production and purification for the treatment of creatine-deficient patients.
In 2021, he obtained a Master’s Degree in Medical, Veterinary and Pharmaceutical Biotechnology at the University of Parma. The thesis was focused on the identification and the isolation of human monoclonal antibodies against the antibiotic-resistant Klebsiella pneumoniae strains. This work was developed in the MAD-Lab group at Fondazione Toscana Life Sciences in Siena led by Dr. Rino Rappuoli.
In the October 2021, during his first PhD year, he has joined VisMederi company in Siena, where he evaluate the neutralizing potency of monoclonal antibodies produced as prophylaxis or therapy against the SARS-CoV-2 virus. In addition, he investigate the ability of SARS-CoV-2 virus to escape the antibody response. This experiments were performed in Biosafety Level 3 (BSL-3) laboratories.
In December 2022, Giulio is continue the doctoral research project in the MAD-Lab group at Fondazione Toscana Life Sciences. In detail, he is involved in the “MabCo19”, a project focused on the identification and characterization of neutralizing human monoclonal antibodies isolated from subjects vaccinated against SARS-CoV-2 virus and/or from convalescent who had been SARS-CoV-2 infected.
